REFERENCES
- Alpert J. E. Drug-drug Interactions. Psychopharmacology. Presented at Symposium hosted by Massachusetts General Hopstial Department of Psychiatry Division of Postgraduate Education, Boston, MA, September, 2005
- Brannan S. K., Mallinckrodt C. H., Detke M. J., Watkin J. G., Tollefson G. D. Onset of action for duloxetine 60 mg once daily: Double-blind, placebo-controlled studies. Journal of Psychiatric Research 2005; 39: 61–172, [CSA]
- Drake M., Lu U., Goldsteing D. J., Hayes J. R., Demitrack M. A. Duloxetine, 60 g once daily, for major depressive disorder: A randomized double blind placebo-controlled trial. The Journal of Clinical Psychiatry 2002; 63: 308–315, [CSA]
- Eli Lilly Company. December 14, 2005, Cymbalta (PV 3606 AMP). Retrieved on April 10, 2006, from http://pi.lilly.com/us/cymbalta-pi.pdf
- Goldstein D. J., Lu Y., Detke M. J., Wiltse C., Mallinckrodt C., Demitrack M. A. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. Journal of Clinical Psychopharmacology 2004; 24(4)389–399, [INFOTRIEVE], [CROSSREF], [CSA]
- Hudson J. I., Wolreich J. J., Kajdasz D. K., Mallinckrodt C. H., Watkin J. G., Martynov O. V. Safety and tolerability of duloxetine in the treatment of major depressive disorder analysis of pooled data from eight placebo-controlled clinical trials. Human Psychopharmacology: Clinical and Experimental 2005; 20: 327–341, [CROSSREF], [CSA]
- Stahl S. Essential psychopharmacology: Neuroscientific basis and practical applications. Cambridge University Press, New York 2000
- Stahl S. Essential psychopharmacology: The prescriber's guide. Cambridge University Press, New York 2004
- Wohlreich M. M., Watkin J. G. The role of duloxetine in the treatment of depression and associated painful physical symptoms. Prim Care Companion J Clin Psychiatry 2003; 5(6)286–287, [INFOTRIEVE], [CSA]